Hsien-Hsien Lei

Hsien-Hsien Lei

Vice President Communications and Value-Based Healthcare, Asia Pacific at Medtronic

Medical Devices
  1. Asia Pacific Medical Technology Association (APACMed),
  2. Medtronic,
  3. American Chamber of Commerce in Singapore
  1. Ogilvy CommonHealth Asia Pacific (formerly Ogilvy Health),
  2. Ogilvy Health,
  3. Ogilvy Health, Singapore
  1. Johns Hopkins University Bloomberg School of Public Health
Recommendations22 people have recommended Hsien-Hsien Lei
  1. Portfolio
500+ connections

View Hsien-Hsien Lei’s full profile. It's free!

Your colleagues, classmates, and 500 million other professionals are on LinkedIn.

Hsien-Hsien Lei’s Posts

  • PLOW Ahead

    With a new day comes new strength and new thoughts. ~Eleanor Roosevelt On International Womens Day, Im excited to launch a new movement that I hope will give everyone the courage to PLOW...


Commercially-savvy and strategic healthcare specialist with entrepreneurial spirit. Deep understanding of the healthcare industry and proven success in driving business growth under market and resourcing pressures. Strong leadership and managerial experience developed on-the-job and through industry leading training programs. Trusted advisor to clients in pharma, medical technology, consumer health, government and other healthcare industry sectors.

As a writer, I have been recognized by Forbes, FOX News, Nature Reviews Genetics, Duke GenomeLIFE Magazine, Detroit Free Press, The Washington Post, Los Angeles Times, Federal Computer Week, CDC Genomics & Health Weekly Update, and Science.

Previous countries of residence: USA, Taiwan, Vietnam, Japan, UK, Singapore

Languages: English, Mandarin Chinese, and Japanese

Specialties: advertising and promotions, branding, digital, social media, epidemiology, genetics, genomics, dna, science, science communications, health, social networking, personalized medicine, medical and scientific writing and editing, copywriting, medical education, public relations, PR, medical communications, healthcare communications


  • Chair, Communications Committee

    Asia Pacific Medical Technology Association (APACMed)
    – Present (1 year 10 months)

    To bring the APACMed Mission to life focusing on Access, Innovation and Collaboration

    The Communications Committee works with the APACMed Secretariat to:

    - Develop the Communications strategy
    - Ensure consistency of positioning and messaging across all content and promotional materials
    - Raise the profile and reputation of APACMed
    - Educate target audiences about the value the medtech industry brings to healthcare and how medtech improves patient outcomes

  • Vice President Communications and Value-Based Healthcare, Asia Pacific

    – Present (2 years 9 months)

    Responsible for Medtronic internal and external communications across Korea, Japan, India, Australia & New Zealand and Southeast Asia. Member of the Asia Pacific Leadership Team and Global Communications Leadership Team. Chair of the Medtronic APAC Value-based Healthcare Council and member of the Global Value-based Healthcare Council.

    Developing strategies and execution plans to engage internal and external stakeholders in meaningful, actionable relationships and conversations that enhance and grow Medtronic’s reputation and business results in the region.

    Working with the Global and Asia Pacific Communications Teams to ensure consistent branding and communications, manage issues and crises, provide consistent and compelling employee communication and lead the conversion to a strong digital and social media enterprise.

  • Governor

    American Chamber of Commerce in Singapore
    – Present (4 years 9 months)

    Elected to the Board of Governors in May 2017

    Co-Chair of the Healthcare Committee from July 2013 - May 2017
    - Plan monthly networking meetings at which industry experts present on topics of interest
    - Produce policy papers for AmCham Singapore to be shared with the Singapore government
    - Strengthen relationships between member organizations in the Singapore healthcare industry and in the Asia-Pacific region

  • General Manager

    Ogilvy CommonHealth Asia Pacific (formerly Ogilvy Health)
    (2 years 7 months)
  • Director

    Ogilvy Health
    (2 years)
  • Scientific Advisor and Medical Education Lead

    Ogilvy Health, Singapore
    (11 months)
  • Regional Content and Social Media Manager

    Soho Square
    (1 year)
  • Media Consultant

    Human Genome Organisation (HUGO)
    (7 months)
  • Co-Founder

    The DNA Network
    (3 years)
  • Publisher and Writer

    (3 years)
  • Independent Consultant

    Epidemiology and Biotechnology
    (11 years)
  • Genetic Information Specialist

    DNA Direct
    (1 year 1 month)
  • Science and Health Editor

    (2 years 1 month)
  • Family and Relationships Editor

    (2 years)
  • Science Editor

    Universal Academy Press
    (1 year 7 months)
  • Post-Doctoral Fellow

    National Taiwan University Hospital
    (1 year 1 month)
  • Genetic Epidemiology Consultant

    (11 months)
  • Research Associate

    National Institute of Allergy and Infectious Diseases (NIAID)
    (less than a year)
  • Research Assistant

    Stanford University Hospital
    (less than a year)
  • Epidemiology Intern

    County of San Mateo
    (less than a year)
  • Pharmacy Clerk

    Kaiser Permanente
    (2 years)


  • Johns Hopkins University Bloomberg School of Public Health

  • Stanford University

  • The Jackson Laboratory


  • Science
  • Medical Education
  • Corporate Communications
  • Copywriting
  • Social Media
  • Blogging
  • Public Relations
  • Editing
  • Genetics
  • Genomics
  • Advertising
  • Epidemiology
  • Medical Writing
  • DNA
  • Business Development
  • Bioinformatics
  • Digital Marketing
  • CRM
  • Brand Development
  • Content Development
  • Digital Strategy
  • Creative Strategy
  • Event Planning
  • Crisis Communications
  • Content Strategy
  • Data Analysis
  • Web 2.0
  • Medical Communications
  • Science Communication
  • Healthcare Communications
  • Health Communication
  • Personalized Medicine
  • Social Networking
  • Editorial
How's this translation?
  • Great
  • Has errors
Thanks for your help!

Honors & Awards

  • Global Health & Travel Women of Substance

  • Ogilvy & Mather Asia Pacific Women to Watch

  • Program Director, Ogilvy & Mather Masterclass

    Integrated agency training for up-and-coming junior staff at Ogilvy & Mather.

  • New Leaders Development Program

    Ogilvy & Mather

    NLDP is aimed at Ogilvy's up-and-coming young leaders and covers core components of managerial and leadership skills.

  • The "No" Man Award - The Way of the David Award

    Ogilvy & Mather Singapore

    The antithesis of the "yes" man and known for making some hard calls. You are the wise voice of dissent when everyone else says Go or Okay.

  • Delta Omega Public Health Honor Society, Lifetime Member

    Delta Omega Public Health Honor Society

  • Blue Ribbon Abstract

    American Society of Nephrology

  • Cardiovascular Epidemiology Pre-Doctoral Training Fellowship

    National Institutes of Health



  • Japanese

    Elementary proficiency

  • English

    Native or bilingual proficiency

  • Mandarin Chinese

    Professional working proficiency


  • Familial aggregation of bothersome benign prostatic hyperplasia symptoms


    These findings confirm previous findings that family history and early age of onset are associated with an increased risk of BPH and that the most likely mode of inheritance is autosomal dominant or codominant. Bothersome BPH appears to have a weaker genetic component than more restrictive definitions of hereditary BPH. Thus, linkage studies are more likely to be successful if they focus on stricter definitions of hereditary BPH (eg, early onset, large volume, strong family history) rather than symptomatic or clinical BPH.

    • Hsien-Hsien Lei,
    • Jay D Pearson,
    • Terri H Beaty,
    • Kathleen E Wiley,
    • Sarah D Isaacs,
    • William B Isaacs,
    • Elizabet Stoner,
    • Patrick C Walsh
  • Sibling-based association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study

    Journal of Molecular Medicine

    To address the role of PPARγ2 in glucose homeostasis and insulin sensitivity, among many other objectives, we conducted a sibling-controlled association study in a multicenter program – the Stanford Asian-Pacific Program in Hypertension and Insulin Resistance (SAPPHIRe). Approximately 2525 subjects in 734 Chinese and Japanese families have been recruited from six field centers for SAPPHIRe. In total, 1702 subjects including parents and siblings from 449 families have been genotyped for PPARγ2, of which 328 families were Chinese and 121 Japanese. Only 88 subjects of the 1525 siblings screened for the P12A polymorphism were found to be carriers of the A variant, the most common variant of the PPARγ2 gene. A variant frequencies of the siblings were 4.27% in Chinese and 2.72% in Japanese. Specifically, we examined whether there were differences in metabolic variables between the discordant siblings within families. In total, 88 subjects carrying either 1 or 2 A alleles had at least one sibling who was discordant for the P12A polymorphism, yielding a total of 180 individuals from 47 families for analyses, among which 92 siblings were homozygous for wild-type P allele. Siblings with the A variant tended to have lower levels of fasting plasma glucose (OG-10), and lower glucose levels at 60 min following oral glucose loading after adjusting for age, gender, and body mass index. Using a mixed model treating family as a random effect, we found that P12A polymorphism of the PPARγ2 gene contributes significantly to the variance in fasting plasma glucose, glucose level at 60 min, and insulin-resistance homeostasis model assessment. Our results suggest that within families siblings with the A variant in the PPARγ2 gene may be more likely to have better glucose tolerance and insulin sensitivity independent of obesity in Chinese and Japanese populations.

    • Hsien-Hsien Lei,
    • Lee-Ming Chuang,
    • Chao Hsiung,
    • Yii-Der Chen,
    • Low-Tone Ho,
    • Wayne H.-H. Sheu,
    • Dee Pei,
    • Craig H. Nakatsuka,
    • David Cox,
    • Richard E. Pratt,
    • Tong-Yuan Tai
  • Peroxisome proliferator—activated receptor gamma 2 pro12ala gene variant is strongly associated with larger body mass in the Taiwanese


    he peroxisome proliferator—activated receptor gamma 2 (PPARγ2) has been studied extensively because of its putative role in adipocyte differentiation and insulin sensitivity. The association of the Pro12Ala and Pro115Gln PPARγ2 gene variants with type 2 diabetes mellitus, the body mass index (BMI), and other diabetes-related phenotypes was examined in the Taiwanese population. Genotypes were determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis. Allele frequencies were compared between 280 subjects with type 2 diabetes mellitus and 310 subjects without diabetes using the chi-square test. Continuous phenotype analysis was performed by multiple logistic regression adjusting for age and BMI where appropriate. There was no significant association between the Pro12Ala gene variant and type 2 diabetes; the frequency of the Ala12 allele was 0.03 in type 2 diabetics and 0.04 in nondiabetics (P = .40). The Gln115 allele was not detected in any of the cases or controls. In multiple linear regression analysis of all cases and controls combined adjusted for age, sex, and diabetic status, carriers of the Ala12 allele had a mean BMI of 25.9 ± 0.5 kg/m2 (mean ± SE), compared with 24.2 ± 0.1 kg/m2 in Pro12 homozygotes (P < .001). In addition, carriers of the Ala12 allele have a 2.9 times (95% confidence interval [CI], 1.5 to 5.5) higher odds of having a BMI of at least 25 kg/m2. These results suggest that in the Taiwanese, the Pro12Ala PPARγ gene variant may contribute to fat accumulation and a higher BMI independent of type 2 diabetes. These results need to be confirmed in future studies, as a linkage disequilibrium of this variant with other mutations cannot be ruled out.

    • Hsien-Hsien Lei,
    • M.H. Chen,
    • W.S. Yang,
    • M.C. Chiu,
    • M.C. Chen,
    • T.Y. Tai,
    • L.M. Chuang
  • Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population

    Clinical Endocrinology

    Vitamin D receptor gene polymorphisms were associated with type 1 diabetes in a Taiwanese population. However, functional studies are needed to establish the role of the vitamin D receptor in the pathogenesis of type 1 diabetes mellitus.

    • Hsien-Hsien Lei,
    • Tien-Jyun Chang,
    • Jih-I Yeh,
    • Ken C. Chiu,
    • Kuan-Ching Lee,
    • Mei-Chu Chen,
    • Tong-Yuan Tai,
    • Lee-Ming Chuang
  • Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study


    We conducted a community-based case-control study of African-American men and women in the Atherosclerosis Risk in Communities Study. The allele frequencies of the Gly972Arg variant of the insulin receptor substrate-1 (IRS-1) gene and the Ala54Thr variant of the fatty acid binding protein 2 (FABP2) gene were compared in 992 normal control subjects and three patient groups: 1) 321 type 2 diabetic individuals, 2) 260 severely obese individuals, and 3) 258 markedly hyperinsulinemic individuals without diabetes. Allele frequencies of Gly972Arg IRS-1 and Ala54Thr FABP2 were 0.07 and 0.22, respectively; there were no differences in allele or genotype frequencies between patients and control subjects for either gene variant. In weighted linear regression of all patients and control subjects, the presence of the IRS-1 gene variant was associated with a 0.85 (0.42) kg/m2 higher BMI (P = 0.04). In addition, individuals with at least one IRS-1 Arg972 allele and two FABP2 Thr54 alleles had a BMI of 33.3 (7.9) kg/m2, compared with 30.0 (6.3) kg/m2 for those with neither allele (P = 0.05). These results suggest that in African-Americans, these variants in the IRS-1 and FABP2 genes are not associated with the risk of type 2 diabetes, severe obesity, or marked hyperinsulinemia, but that their independent and joint effects may be associated with small increases in BMI.

  • Familial aggregation of renal disease in a population-based case-control study

    Journal of the American Society of Nephrology

    Family history of renal disease has been associated with an increased risk of end-stage renal disease (ESRD). It is uncertain whether this risk is mediated by familial aggregation of risk factors for ESRD, such as diabetes and hypertension. The association of ESRD with familial aggregation of renal disease was examined in a large, population-based case-control study conducted in Maryland, Virginia, West Virginia, and Washington, DC. The number of first-degree relatives who were affected with any type of renal disease was compared between 689 newly treated ESRD patients registered in the Medicare ESRD program (92% of all eligible incident cases presenting between January and July of 1991) and 361 control subjects without ESRD who were selected by random-digit dialing (90% response rate). Patients and control subjects were frequency matched by age; patients with ESRD caused by polycystic kidney disease and other known hereditary kidney diseases were excluded. Analysis was conducted using multiple logistic regression. After controlling for the proband's age, gender, race, family size, socioeconomic status, and personal and family histories of diabetes and hypertension, having one first-degree relative with renal disease increased the odds of ESRD by 1.3 (95% confidence interval, 0.7 to 2.6) and having two or more affected first-degree relatives increased the odds of ESRD by 10.4 (95% confidence interval, 2.7 to 40.2). These data support familial aggregation of renal disease in excess of that predicted by clustering of diabetes and hypertension within families, suggesting that either genetic susceptibility or environmental exposures shared within families increase the risk of developing ESRD. This risk is also much higher when two or more first-degree relatives have renal disease. Unraveling the molecular basis of this increase in risk may provide new avenues for treatment and prevention of ESRD.

  • Bladder cancer and drinking water: a population-based case-control study in Washington County, Maryland (United States)

    Cancer Causes & Control

    A population-based case-control study was conducted in WashingtonCounty, Maryland (United States) to explore the association between incidentbladder cancer and exposure to drinking water from chlorinated surfacesources. Cancer cases were White residents, enumerated in a 1975 countycensus and reported to the Washington County Cancer Registry (n = 294)between 1975 and 1992. White controls, frequency matched by age (± 5 years)and gender, were selected randomly from the census (n = 2,326). Householdsreceiving municipal water, which generally derived from chlorinated surfacewaters, were treated as having ‘high exposure‘ and all others, as ‘lowexposure.’ Duration of exposure to type of drinking water was based on lengthof residence in the census household prior to 1975. Odds ratios (OR) werecalculated using logistic regression methods, adjusting for age, gender,tobacco use, and urbanicity. Bladder cancer risk was associated weakly in thegeneral population with duration o f exposure to municipal water. Theassociation was limited to those who had smoked cigarettes. In ever-smokerscompared with never-smokers with low exposure, the adjusted ORs for bladdercancer risk with increasing exposure were 1.3, 1.4, 1.4, 1.7, 2.2, 2.8,respectively, for 0, 1-10, 11-20, 21-30, 31-40, > 40 years' exposureduration. The ORs in smokers were not diminished after adjusting for smokinghistory and intensity.

    • Hsien-Hsien Lei,
    • D. M. Freedman,
    • K. P. Cantor,
    • N. L. Lee,
    • L.-S. Chen,
    • C. E. Ruhl
  • Transfection of Plasmodium falciparum within human red blood cells

    Proceedings of the National Academy of Sciences of the United States of America

    Plasmodium falciparum malaria parasites within human red blood cells (RBCs) have been successfully transfected to produce chloramphenicol acetyltransferase (CAT). Electroporation of parasitized RBCs was used to introduce plasmids that have CAT-encoding DNA flanked by 5' and 3' untranslated sequences of the P. falciparum hsp86, hrp3, and hrp2 genes. These flanking sequences were required for expression as their excision abolished CAT activity in transfected parasites. Transfection signals from native CAT-encoding DNA compared well with those from a synthetic DNA sequence adapted to the P. falciparum major codon bias, demonstrating effective expression of the bacterial sequence despite its use of rare P. falciparum codons. Transfected ring-stage parasites produced CAT signals at least as strong as transfected schizont-stage parasites even though ring stages are surrounded by more RBC cytoplasm than schizonts. The transfection of erythrocyte-stage P. falciparum parasites advances our ability to pursue genetic analysis of this major pathogen.




    Corporate Member


A preview of what LinkedIn members have to say about Hsien-Hsien:

  • It has been a real privilege to have worked for and with Hsien, I have not looked back from what has proven to be a truly life-changing experience. I am grateful for all that I have learnt from her about communications, business, people, life, the universe and everything. She is an intellectual powerhouse with a voracious appetite for learning, a creative flair and a great sense of humor. She motivated and supported her team, guiding us and upholding high standards to ensure that we delivered quality work to client. We worked hard and earned the right to be proud of all that we achieved together. Thanks for everything, Hsien - you continue to inspire me with your "can do" attitude, not only to do more, but also to do it better.
  • Hsien is a strong, effective and fair leader who inspires confidence and trust in those who work with her. She is extremely knowledgeable across all aspects of the business and the healthcare industry. Despite her busy schedule, she is always willing to teach and mentor those who are hungry for knowledge – and this is not just for the people working under her. Having worked with Hsien for two years at Ogilvy CommonHealth, I really miss her wit and no-nonsense approach towards work. It was an absolute pleasure and joy – time really does fly when one is having fun. Thank you for all that you have taught me, Hsien!

View Hsien-Hsien Lei’s full profile to...

  • See who you know in common
  • Get introduced
  • Contact Hsien-Hsien Lei directly

People Also Viewed

Public profile badge

Include this LinkedIn profile on other websites

View profile badges

LinkedIn member directory:

  1. a
  2. b
  3. c
  4. d
  5. e
  6. f
  7. g
  8. h
  9. i
  10. j
  11. k
  12. l
  13. m
  14. n
  15. o
  16. p
  17. q
  18. r
  19. s
  20. t
  21. u
  22. v
  23. w
  24. x
  25. y
  26. z
  27. more